New Zealand – Healthcare, Regulatory and Reimbursement Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

GlobalData, the industry analysis specialist, has released its latest report, “New Zealand – Healthcare, Regulatory and Reimbursement Landscape”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in New Zealand. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

The New Zealand pharmaceutical market is one of the major pharmaceutical markets of the Southwestern Pacific region that increased from $0.65B in 2011 at a Compound Annual Growth Rate (CAGR) of 7% to $0.98B in 2019. It is forecast to reach about $1.47B in 2025. The growth in the market is attributed to high levels of research and development, growing elderly population, and a strong clinical trial environment. However, an underfunded medicine budget and increased timelines for medicine funding pose barriers to the pharmaceutical industry. The New Zealand medical devices market was estimated to be $0.92B in 2015, which increased at a CAGR of 6% to reach $1.24B in 2020. The market is expected to grow at a CAGR of 5% from to reach $1.59B in 2025.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in New Zealand, and includes:

An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

Profiles and SWOT analyses of the major players in the pharmaceutical market: Roche, GSK, Pfizer, AstraZeneca, and Blis Technologies.

Profiles and SWOT analyses of the major players in the medical device market: GE Healthcare, Zimmer Biomet, Alcon, Olympus, and Fisher & Paykel Healthcare.

An insightful review of the COVID-19 epidemiology, COVID-19 impact, and developments in healthcare market, healthtech landscape, reimbursement, and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices

Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure

An overview of the opportunities for and challenges to growth in New Zealand healthcare market

Reasons to Buy

This report will enhance your decision-making capability by allowing you to:

Develop business strategies by understanding the trends shaping and driving New Zealand healthcare market

Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact New Zealand healthcare market in the future

Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

Table of Contents

1. Table of Contents

1.1List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights – Facts about New Zealand Healthcare Market

2.3 Key Highlights: Healthcare Startups in New Zealand

2.4 Key Events: New Zealand Pharmaceutical News, 2015-2021

2.5 Key Events: New Zealand Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019-2020

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, New Zealand, 2020

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Five-Year Action Plan of Ministry of Health, New Zealand, 2015 – 2020

3.3 Pharmaceutical Market – Exports

3.4 Pharmaceutical Market – Imports

3.5 Pharmaceutical Market – Supply Channels, New Zealand

3.6 Pharmaceutical Market – Market Segments

3.7 Major Therapeutic Areas, New Zealand

3.8 COVID-19 Epidemiology, New Zealand

3.9 COVID-19 Impact and Developments, New Zealand

3.10 COVID-19 Clinical Trials Landscape, New Zealand

3.11 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, New Zealand, 2019-2021

6.2 Deal Analysis: Medical Device Market, New Zealand, 2019-2021

7. HealthTech Landscape

7.1 HealthTech Landscape, New Zealand

7.2 HealthTech Deals Landscape, New Zealand

7.3 Adoption of Technology in Healthcare, New Zealand

7.4 Key HealthTech Deals, New Zealand

7.5 Digital Health Regulations, New Zealand

7.6 HealthTech Landscape: Benefits and Risks, New Zealand

8. Market Access

8.1 Overview of Healthcare System, New Zealand

8.2 Drug Reimbursement Process, New Zealand

8.3 Overview of Insurance Providers, New Zealand

8.4 Out-of-Pocket Co-Payments and Safety Nets, New Zealand

8.5 Out-of-Pocket Spending, New Zealand

8.6 Pricing Policies, New Zealand

8.7 Regulatory Landscape, New Zealand

8.7.1 Overview of Regulatory Agencies, New Zealand

8.7.2 Marketing Authorization for Pharmaceutical Products, New Zealand

8.7.3 Marketing Authorization for Generic Medicines, New Zealand

8.7.4 Marketing Authorization for Biosimilars, New Zealand

8.7.5 Marketing Authorization for Medical Devices, New Zealand

8.7.6 Import Regulations, New Zealand

8.7.7 Intellectual Property Rights, Patent, New Zealand

8.7.8 Intellectual Property Rights, Trademark, New Zealand

8.7.9 Clinical Trial Regulation Process, New Zealand

8.7.10 Pharmaceutical Clinical Trials Landscape, New Zealand

8.7.11 Medical Devices Clinical Trials Landscape, New Zealand

8.7.12 Pharmacy License Regulations, New Zealand

8.7.13 Pharmaceutical Advertisement Regulations, New Zealand

8.7.14 Labeling and Packaging Regulations, New Zealand

9. Country Healthcare Landscape

9.1 Healthcare Policy Highlights, New Zealand

9.2 Healthcare Facilities, New Zealand

9.3 Healthcare Parameters, New Zealand

9.4 Life Expectancy and Immunization Rate, New Zealand

9.5 Environmental Health, New Zealand

9.6 Healthcare Personnel, New Zealand

9.7 Disease Burden, US New Zealand

9.8 Healthcare Expenditure, New Zealand

11 Trade Associations, Conferences, and Trade Fairs, New Zealand

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Approved Biosimilars, New Zealand, 2019-2020

Table 2: COVID-19 Indicators (Number of cases), New Zealand and Global, 2020-2021

Table 3: COVID-19-Related Travel Restrictions, New Zealand, 2020-2021

Table 4: Objectives of the National COVID-19-Testing Strategy (Five Parts), New Zealand, 2020

Table 5: Available COVID-19-Vaccines,New Zealand, 2020-2021

Table 6: COVID-19 Vaccine Rollout Plan, New Zealand, 2020-2021

Table 7: List of COVID-19 Clinical Trials Sponsors by Count, New Zealand, 2020-2021

Table 8: Medical Devices Market, New Zealand, Major Segments ($M), 2020

Table 9: Anesthesia & Respiratory Devices Market, New Zealand, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 10: Orthopedic Devices Market, New Zealand, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 11: General Surgery Devices Market, New Zealand, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 12: In Vitro Diagnostic Devices Market, New Zealand, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 13: Cardiovascular Devices Market, New Zealand, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 14: Typical Patient Copayments and Safety Nets, New Zealand, 2019

Table 15: NMA Fee, New Zealand, 2019

Table 16: Patent Application Fee, New Zealand, 2020

Table 17: Trademark Application Fee, New Zealand, 2020

Table 18: Clinical Trial Application Fee, New Zealand, 2019

Table 19: Conferences and Trade Fairs, New Zealand, 2021

Figures

Figure 1: Pharmaceutical Market, New Zealand, Revenue ($B and NZD), 2013-2020

Figure 2: Medical Device Market, New Zealand, Revenue ($B), 2015-2020

Figure 3: Healthcare Start-Ups in New Zealand, 2020

Figure 4: Country Profile, New Zealand, 2020

Figure 5: Pharmaceutical Market, New Zealand, Revenue ($B), 2011-2019

Figure 6: Pharmaceutical Market, New Zealand, Revenue Forecast ($B), 2020-2025

Figure 7: Focus Areas of Five-Year Action Plan of Ministry of Health, New Zealand, 2015-2020

Figure 8: Pharmaceutical Exports ($M), New Zealand, 2011-2020

Figure 9: Top Export Partners, New Zealand, 2020

Figure 10: Pharmaceutical Imports ($M), New Zealand, 2011-2020

Figure 11: Top Import Partners, New Zealand, 2020

Figure 12: Pharmaceutical Supply Channel, New Zealand, 2016

Figure 13: Medicine Supply Issue Management, PHARMAC, New Zealand, 2020

Figure 14: Generic Drugs Usage (% share by volume), New Zealand, 2010-2019

Figure 15: Generic Drugs Usage (% share by value), New Zealand, 2010-2019

Figure 16: OTC Market, New Zealand, Revenue ($M), 2013-2020

Figure 17: OTC Market by Drug Category, Revenue ($M), New Zealand, 2020

Figure 18: OTC Medicines Market, Major Distribution Channels ($M), New Zealand, 2020

Figure 19: Pharmaceutical Sales by Drug Category ($M), New Zealand, 2020

Figure 20: Major Therapeutic Areas by Pharmaceutical Sales ($M), New Zealand, 2017-2019

Figure 21: COVID-19 (Number of cases), New Zealand, 2020-2021

Figure 22: COVID-19 (Number of deaths), New Zealand, 2020-2021

Figure 23: COVID-19 Fiscal Stimulus Timeline, New Zealand, 2020-2021

Figure 24: COVID-19 Vaccine Administration, Number of Vaccines Administered, New Zealand, 2020-2021

Figure 25: Top COVID-19 Markets by Product Categories (Number of available marketed products), New Zealand, 2020-2021

Figure 26: Top COVID-19 IVD Products by Device Class (Number of available marketed products), New Zealand, 2020-2021

Figure 27: COVID-19 Clinical Trials Count by Phase, New Zealand, 2020-2021

Figure 28: COVID-19 Clinical Trials Count by Trial Status, New Zealand, 2020-2021

Figure 29: Medical Devices Market, New Zealand, Revenue ($B), 2015-2020

Figure 30: Medical Devices Market, New Zealand, Revenue Forecast ($B), 2021-2025

Figure 31: Medical Devices Market, New Zealand, Major Segments (%), 2020

Figure 32: Anesthesia & Respiratory Devices Market, New Zealand, Revenue ($M), 2015-2022

Figure 33: Anesthesia & Respiratory Devices Market, New Zealand, Market Share of Major Players (%), 2020

Figure 34: Orthopedic Devices Market, New Zealand, Revenue ($M), 2015-2022

Figure 35: Orthopedic Devices Market, New Zealand, Market Share of Major Players (%), 2020

Figure 36: General Surgery Devices Market, New Zealand, Revenue ($M), 2015-2022

Figure 37: General Surgery Devices Market, New Zealand, Market Share of Major Players (%), 2020

Figure 38: In Vitro Diagnostic Devices Market, New Zealand, Revenue ($M), 2015-2022

Figure 39: In Vitro Diagnostic Devices Market, New Zealand, Market Share of Major Players (%), 2020

Figure 40: Cardiovascular Devices Market, New Zealand, Revenue ($M), 2015-2022

Figure 41: Cardiovascular Devices Market, New Zealand, Market Share of Major Players (%), 2020

Figure 42: Diagnostic Market, New Zealand, Revenue ($M), 2015-2020

Figure 43: Diagnostic Market, New Zealand, Revenue Forecast ($M), 2021-2025

Figure 44: Medical Devices Market, New Zealand, Revenue ($B) of Major Companies, 2019

Figure 45: Deal Value and Deal Count, Pharmaceutical Market, New Zealand, 2019-2021

Figure 46: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, New Zealand, 2019-2021

Figure 47: Deal Value and Deal Count Subtypes, Pharmaceutical Market, New Zealand, 2019-2021

Figure 48: Top Therapy Areas by Deal Value, Pharmaceutical Market, New Zealand, 2019-2021

Figure 49: Mergers and Acquisitions by Quarter, Pharmaceutical Market, New Zealand, 2019-2021 (by value and by number)

Figure 50: Top Therapy Areas by Deal Count, Pharmaceutical Market, New Zealand, 2019-2021

Figure 51: Deal Value and Deal Count, Medical Devices Market, New Zealand, 2019-2021

Figure 52: Deal Value and Deal Count, Quarterly, Medical Devices Market, New Zealand, 2019-2021

Figure 53: Deal Value and Deal Count Subtypes, Medical Devices Market, New Zealand, 2019-2021

Figure 54: Top Equipment Sectors by Deal Value, Medical Devices Market, New Zealand, 2019-2021

Figure 55: Top Equipment Sectors by Deal Count, Medical Devices Market, New Zealand, 2019-2021

Figure 56: M&A Deals by Equipment Sector, Medical Devices Market, New Zealand, 2019-2021 (by value and by number)

Figure 57: Components of Digital Health Strategy, New Zealand, 2016-2020

Figure 58: Themes of Digital Health Strategy, New Zealand, 2018-2026

Figure 59: Digital Health Vision Focus Areas, New Zealand, 2018-2026

Figure 60: Deal Value ($M), HealthTech, New Zealand, 2019-2021

Figure 61: Deal Count (Number of Deals), HealthTech, New Zealand, 2019-2021

Figure 62: Principles for the Safe and Effective Use of Data and Analytics, New Zealand, 2018

Figure 63: Principles of Privacy Act 1993, New Zealand

Figure 64: Key Health Sector Organizations and People, New Zealand

Figure 65: Overview of Health System, New Zealand, 2020

Figure 66: PHARMAC Funding Criteria, New Zealand, 2020

Figure 67: Reimbursement Process, New Zealand, 2020

Figure 68: Private Health Insurance (% of total population), New Zealand, 2012-2019

Figure 69: Out-of-Pocket Spending (% of health spending), New Zealand, 2010-2018

Figure 70: Change in Pharmaceutical Price Index (2015 = 100), New Zealand, 2012-2020

Figure 71: Commercial Strategies Used by PHARMAC, New Zealand, 2020

Figure 72: Marketing Authorization for Pharmaceutical Products, New Zealand, 2019

Figure 73: Licensure of a Biosimilar Product, New Zealand, 2020

Figure 74: WAND Process for Medical Devices Approval, New Zealand, 2019

Figure 75: Patent Approval Process, New Zealand, 2019

Figure 76: Trademark Registration Process, New Zealand, 2019

Figure 77: Clinical Trial Approval Process, New Zealand, 2018

Figure 78: Pharmaceutical Clinical Trials Count by Trial Status, New Zealand, 2019-2021

Figure 79: Pharmaceutical Clinical Trials Count by Phase, New Zealand, 2019-2021

Figure 80: Pharmaceutical Clinical Trials Count by Indication, New Zealand, 2019-2021

Figure 81: Top Five Pharmaceutical Clinical Trials Sponsors by Count, New Zealand, 2019-2021

Figure 82: Medical Devices Clinical Trials Count by Trial Status, New Zealand, 2019-2021

Figure 83: Medical Devices Clinical Trials Count by Indication, New Zealand, 2019-2021

Figure 84: Medical Devices Clinical Trials Count by Device Category, New Zealand, 2019-2021

Figure 85: Top Five Medical Devices Clinical Trials Sponsors by Count, New Zealand, 2019-2021

Figure 86: Number of Hospitals (number), New Zealand, 2012-2019

Figure 87: Total Number of Diagnostic Equipment Units (number), New Zealand, 2012-2018

Figure 88: Number of Hospital Beds (per 1,000 Population), New Zealand, 2012-2019

Figure 89: Number of Acute Care Beds (per 1,000 Population), New Zealand, 2012-2019

Figure 90: Number of Psychiatric Care Beds (per 1,000 Population), New Zealand, 2012-2019

Figure 91: Life Expectancy at Birth (Years), New Zealand, 2012-2018

Figure 92: Immunization Rate (% of children immunized), New Zealand, 2012-2019

Figure 93: PM2.5 (µg per m3), New Zealand, 2012-2019

Figure 94: CO2 Emissions (Mt CO2), New Zealand, 2012-2019

Figure 95: Physicians (per 1,000 Population), New Zealand, 2012-2018

Figure 96: Dentists (per 1,000 Population), New Zealand, 2012-2018

Figure 97: Pharmacists (per 1,000 Population), New Zealand, 2012-2019

Figure 98: Nurses (per 1,000 Population), New Zealand, 2012-2018

Figure 99: Major Causes of Male Mortality (number of deaths), New Zealand, 2019

Figure 100: Major Causes of Mortality (number of deaths), New Zealand, 2019

Figure 101: Major Causes of Female Mortality (number of deaths), New Zealand, 2019

Figure 102: Disability-Adjusted Life Years by Major Disease (‘000), New Zealand, 2019

Figure 103: Healthcare Expenditure as Percentage of GDP (%), New Zealand, 2012-2019

Figure 104: Public-Private Share (%), New Zealand, 2012-2019

Figure 105: Opportunities and Challenges

Frequently asked questions

New Zealand – Healthcare, Regulatory and Reimbursement Landscape thematic reports
Currency USD
$1,995

Can be used by individual purchaser only

$5,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

New Zealand – Healthcare, Regulatory and Reimbursement Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at New Zealand – Healthcare, Regulatory and Reimbursement Landscape in real time.

  • Access a live New Zealand – Healthcare, Regulatory and Reimbursement Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.